Howard Petty, CEOA diagnosis of early breast cancer sets off a cascade of decisions: surgery, radiation, endocrine therapy, and years of follow-up. Yet one question often remains harder to answer than any other: Will this cancer actually come back?
Modern medicine is highly effective at detecting early breast lesions. What it has struggled with is distinguishing which of those lesions are biologically aggressive and which are unlikely to recur. Without precise prognostic tools, treatment decisions are frequently guided by population-level risk models rather than by the individual biology of a patient’s tumor.
Predictoma is built to understand which cancer truly matters.
The company applies AI-driven spatial image analysis to evaluate recurrence-associated cell populations within tumor tissue. Rather than identifying cancer alone, the platform analyzes biomarker distribution patterns to determine whether a tumor is likely to recur or remain indolent.
“Designed for seamless integration into existing clinical laboratories, our software delivers patient-specific prognoses with greater than 95 percent accuracy,” says Howard Petty, CEO.
By distinguishing between aggressive and non-aggressive disease—often years before recurrence would otherwise become clinically evident—the platform supports more informed surgical, therapeutic, and surveillance decisions. Existing CPT pathways enable reimbursement, and the system has demonstrated no racial bias in prognostic performance. Predictoma is currently progressing through FDA review as it prepares for clinical deployment.
Precision Without Operational Disruption
How does Predictoma integrate into existing clinical laboratory workflows?
A defining feature of Predictoma’s approach is its compatibility with current clinical laboratory workflows. The platform is designed to operate within existing CLIA-certified laboratory environments. No new microscopes. No proprietary scanners. No capital equipment purchases.
Laboratories continue using established slide preparation processes and reagents. The only additional step is capturing digital images and securely uploading them to Predictoma’s software for analysis.
This simplicity is intentional. Many AI-enabled diagnostics face barriers not because of scientific limitations but because of operational friction. Predictoma’s model is structured as a plug-and-play service: perform the assay, upload the images, and receive a prognostic report.
Importantly, laboratories retain their existing billing structures. Established CPT codes support reimbursement, allowing integration without renegotiating payment models. Most downstream revenue remains with the laboratory, creating alignment between clinical adoption and financial sustainability.
The result is a solution that large reference laboratories, hospital-based laboratories, and regional facilities can implement without significant infrastructure changes.
-
Designed for seamless integration into existing clinical laboratories, our software delivers patient-specific prognoses with greater than 95 percent accuracy.
The result is a solution that large reference laboratories, hospital-based laboratories, and regional facilities can implement without significant infrastructure changes.
Patient-Centered by Design
How can recurrence stratification influence treatment intensity decisions?
For patients diagnosed with early breast cancer, treatment decisions carry lasting physical and psychological implications. Surgical intervention may involve permanent physical changes. Radiation and endocrine therapies can introduce prolonged side effects. Even when risk is low, years of follow-up treatment can impose ongoing emotional strain.
Predictoma aims to provide clearer biological guidance in these decisions.
By identifying patients who are unlikely to experience recurrence, clinicians may feel more confident recommending less intensive management strategies when appropriate. Conversely, patients whose tumors demonstrate aggressive biology can be identified earlier, allowing for more focused intervention.
The platform has undergone extensive validation to assess performance across patient populations. Following refinement and testing, Predictoma reports no racial bias in prognostic accuracy, performing consistently across demographic groups—an important consideration in both clinical practice and regulatory review.
Expanding the Platform: From DCIS to Earlier Disease
How is Predictoma expanding beyond DCIS into broader applications?
Predictoma’s initial clinical focus is ductal carcinoma in situ (DCIS), but the underlying technology extends beyond a single diagnosis.
The company has already applied its spatial image analysis methods to atypical ductal hyperplasia (ADH), an earlier precursor condition. Current management of ADH often involves surveillance due to uncertainty regarding progression risk. Internal validation studies indicate that Predictoma’s platform can identify which ADH patients are more likely to progress long before symptoms emerge.
Approximately 60,000 women are diagnosed with ADH annually in the U.S. Improved risk stratification at this stage could allow surgeons to concentrate intervention on higher-risk patients while minimizing unnecessary procedures for others.
Beyond breast cancer, the company is exploring additional early-stage cancers and translational applications.
Supporting Oncology Drug Development
Predictoma’s technology also has relevance in pharmaceutical development. Therapeutic antibody programs often require extensive early-stage screening to determine whether candidate molecules bind to their intended cellular targets.
Using its spatial biomarker analysis capabilities, Predictoma can evaluate whether antibodies bind specifically to recurrence-driving cell populations within tumor samples. This enables developers to refine candidate lists earlier in the development process, potentially reducing time and cost before entering animal or clinical studies.
An additional application under development involves adapting the platform for use in surgical pathology, with the goal of delivering prognostic insights during operative procedures. While still in development, this extension reflects the broader adaptability of the software platform.
Clinical Insight with Economic Implications
The economic impact of early breast cancer management is substantial, particularly when surgery, adjuvant therapy, and long-term monitoring are considered. By improving recurrence risk stratification, Predictoma has the potential to influence how resources are allocated across patient populations.
Rather than positioning itself as a cost-reduction initiative, the company frames economic benefit as a consequence of improved clinical precision. When high-risk patients are clearly identified and lower-risk patients are not exposed to unnecessary interventions, resource utilization may become more closely aligned with biological need.
Moving Toward Clinical Adoption
Predictoma has built its secure software-as-a-service platform and is entering validation testing with clinical partners as part of the FDA review process. The company anticipates regulatory review of its cybersecurity and technical infrastructure prior to broader deployment.
In parallel, development is underway on next-generation assays, including expanded applications.
In a diagnostics landscape often centered on detecting more disease, Predictoma focuses on understanding disease behavior. By translating spatial biomarker data into actionable prognostic insights, the company seeks to support clinicians in making more individualized treatment decisions.
For laboratories, hospitals, and payers, the approach offers a pragmatic addition to existing workflows. For patients, it provides clearer information at a pivotal moment in care.
Deep Dive
Advancing Precision in Early Breast Cancer Prognosis
Escalating costs and persistent overtreatment continue to define early breast cancer management. Ductal carcinoma in situ and atypical ductal hyperplasia represent large diagnostic cohorts, yet clinical decision-making often relies on tools that do not adequately distinguish indolent disease from lesions likely to recur. Recurrence drives the overwhelming majority of mortality in breast cancer, but most diagnostic workflows are not designed to isolate that risk with sufficient precision. The result is a structural imbalance: women undergo surgery, extended drug therapy and long-term monitoring without clear differentiation between those who will benefit and those who will not.
Executives evaluating AI-based prognostic testing companies must look beyond novelty in image analysis and examine whether a platform can meaningfully stratify recurrence risk at an individual level. Sensitivity and specificity are central. Many legacy diagnostics operate near 70 percent performance thresholds, limiting confidence in de-escalating treatment. A prognostic system that consistently exceeds 95 percent accuracy shifts the economic and clinical equation. It enables payers, hospital systems and laboratory networks to reduce unnecessary surgeries and prolonged therapies while concentrating resources on patients whose disease biology warrants aggressive intervention.
Integration into existing laboratory infrastructure is equally decisive. CLIA laboratories, whether embedded in hospitals, universities or national testing networks, operate under strict reimbursement frameworks and capital constraints. A solution that requires new instrumentation, complex hardware upgrades or workflow redesign introduces friction that slows adoption. In contrast, a platform that works with existing microscopes, staining protocols and imaging processes, and that aligns with established CPT reimbursement pathways, lowers implementation barriers. Subscription-based access to analytic software, rather than capital-intensive equipment purchases, supports scalability across diverse laboratory environments.
Regulatory readiness and cybersecurity discipline also shape purchasing decisions. FDA review processes now extend beyond clinical validity to include data security standards, particularly for cloud-based software as a service models. Executives must assess whether a vendor has built its deployment architecture with these requirements in mind and whether it can support enterprise-grade data protection once commercialized.
Predictoma has positioned its offering at the intersection of these demands. It applies AI-driven image analysis to the spatial distribution of biomarkers in early breast cancer tissue, generating a prognosis that distinguishes recurrent from non-recurrent disease with reported accuracy exceeding 95 percent. Its current focus on ductal carcinoma in situ addresses a population associated with substantial overtreatment and cost exposure, while its pipeline includes prognostic testing for atypical ductal hyperplasia, an even earlier lesion where targeted intervention could prevent progression. The platform operates without new capital equipment, allowing CLIA laboratories to capture reimbursement under existing CPT codes while submitting digital images through a software as a service portal. Ongoing FDA submission efforts, including cybersecurity review, indicate attention to regulatory standards required for clinical deployment.
For executives responsible for long-term clinical value and cost stewardship, Predictoma represents a disciplined approach to AI-based prognostic testing. Its emphasis on recurrence-focused stratification, high diagnostic performance and straightforward laboratory integration aligns with the core imperatives shaping early breast cancer management.
...Read more
AI-based Prognostic Testing Info
Q1
What led Predictoma to be recognized among top AI-based prognostic testing providers?
Predictoma has gained recognition in AI-Based Prognostic Testing by focusing on long-term disease outcome prediction using advanced machine learning models. Its platform is designed to forecast cancer recurrence risk—particularly in breast cancer—over extended time horizons, enabling earlier and more informed clinical decisions. By combining large datasets with predictive analytics, the company delivers insights that go beyond traditional diagnostics, reinforcing its position in AI-Based Prognostic Testing.
Q2
How does Predictoma differentiate its approach to AI-based prognostic testing?
A predictive-first methodology defines how Predictoma delivers AI-Based Prognostic Testing. Rather than focusing solely on diagnosis, its models are trained to analyze patterns in clinical and molecular data to anticipate disease progression and recurrence. This forward-looking approach aligns with emerging trends where AI integrates multimodal data to improve prognostic accuracy and treatment planning.
Q3
How does Predictoma support healthcare and research applications?
Support within Predictoma’s AI-Based Prognostic Testing framework centers on enabling clinicians and researchers to make data-driven decisions. Its software platform is designed to integrate into research and clinical workflows, offering predictive insights that can guide treatment strategies and patient monitoring. By translating complex datasets into actionable outputs, the company ensures that AI-Based Prognostic Testing contributes directly to improved clinical planning and research efficiency.
Q4
What value does Predictoma’s technology bring to patient outcomes?
Earlier risk identification and improved treatment alignment define the value of Predictoma’s AI-Based Prognostic Testing. Predictive models can identify patients at higher risk of recurrence years in advance, allowing for tailored interventions and closer monitoring. AI-driven prognostic tools have shown the ability to outperform traditional methods in predicting outcomes across cancer types, highlighting their clinical potential. These advantages make AI-Based Prognostic Testing a powerful tool for enhancing patient care.
Q5
What role do data and machine learning play in its platform?
Advanced machine learning and large-scale data integration are central to Predictoma’s AI-Based Prognostic Testing. Its models rely on training across extensive clinical datasets to identify patterns that may not be visible through conventional analysis. Research in computational oncology shows that combining clinical, genomic and imaging data significantly improves prognostic predictions, supporting the foundation of platforms like Predictoma.
Q6
Why is Predictoma relevant to the future of precision medicine?
The shift toward personalized healthcare has increased demand for predictive insights, and Predictoma addresses this through AI-Based Prognostic Testing. Its ability to forecast disease trajectories aligns with the broader movement toward precision medicine, where treatments are tailored based on individual risk profiles. As AI continues to enhance prognostic modeling and integrate into clinical workflows, platforms like Predictoma are expected to play a key role in shaping future healthcare strategies.
